189209-27-6

Basic information

• Product Name: O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol
• Synonyms: t-boc-N-amido-PEG6-Amine;t-boc-N-amido-PEG5-Amine;t-boc-N-amido-PEG5-Azide;tert-Butyl (17-amino-3,6,9,12,15-pentaoxaheptadecyl)carbamate;Boc-N-amido-PEG5-Amine;Boc-N-amido-PEG5-Azide;O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol;19-AMino-5,8,11,14,17-pentaoxa-2-azanonadecanoic Acid 1,1-DiMethylethyl Ester
• CAS NO: 189209-27-6
• Molecular Formula: C₁₇H₃₆N₂O₇
• Molecular Weight: 380.47694
• Product Categories: Aliphatics;Amines;Intermediates;Polyethyleneglycol Derivatives;PEGylation Reagents
• Mol File: 189209-27-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• Solubility: Soluble in Water, DMSO, DCM, DMF
• CAS DataBase Reference: O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol(CAS DataBase Reference)
• NIST Chemistry Reference: O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol(189209-27-6)
• EPA Substance Registry System: O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol(189209-27-6)

Safety Data

• Hazardous Substances Data: 189209-27-6(Hazardous Substances Data)

Usage

Description

O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol, also known as t-Boc-N-Amido-PEG5-amine, is a polyethylene glycol (PEG) derivative featuring a Boc-protected PEG linker with a free amino group and five PEG units. O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol is characterized by its hydrophilic PEG spacer, which enhances solubility in aqueous media, and a reactive amino group that can interact with carboxylic acids and activated NHS esters. The Boc group can be deprotected under mild acidic conditions, freeing the amine for further reactions.

Uses

Used in Biochip Technology:
O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol is used as a key component in the preparation of novel biochip technology for the detection of explosives, specifically TNT. Its hydrophilic nature and reactive amino group contribute to the development of sensitive and selective detection methods.
Used in Chemical Synthesis:
In the field of chemical synthesis, O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol serves as a reagent for the synthesis of chemical inducers of dimerization (CID). These CIDs are essential for identifying the protein targets of inhibitors that prevent the invasion of Toxoplasma gondii, a parasitic protozoa responsible for toxoplasmosis.
Used in Pharmaceutical Industry:
O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol is used as a PEG linker for the development of drug conjugates and targeted therapies. The hydrophilic PEG spacer improves the solubility and pharmacokinetic properties of the resulting drug molecules, while the reactive amino group allows for the attachment of various drug payloads or targeting moieties.
Used in Material Science:
In material science, O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol can be utilized as a building block for the synthesis of PEGylated polymers and copolymers with tailored properties. These materials can find applications in various fields, such as drug delivery, tissue engineering, and surface modification for improved biocompatibility.

Upstream product

• 911209-07-9 tert-butyl N-[2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate 
• 331242-61-6 tert-butyl N-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate 
• 430430-57-2 2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecane-13-yl methanesulfonate 
• 1186579-82-7 2-[2-[2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl methanesulfonate 
• 6338-55-2 2-(2-(2-aminoethoxy)ethoxy)ethan-1-ol 
• 5197-62-6 2-[2-(chloroethoxy)ethoxy]ethanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 86520-52-7 2-[2-(2-azidoethoxy)ethoxy]ethanol 
• 139115-92-7 tert-butyl 2-(2-(2-hydroxyethoxy)ethoxy)ethylcarbamate 
• 2615-15-8 pentaethylene glycol 
• 42749-28-0 toluene-4-sulfonic acid 2-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethyl ester 
• 86770-69-6 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-ol 
• 39160-70-8 3,6,9,12,15,18-hexaoxa-1-octadecyl amine 
• 1264015-76-0 2-{2-[2-(2-[2-(2-tert-butoxycarbonylaminoethoxy)ethoxy]ethoxy)ethoxy]ethoxy}ethyl p-tosylate 

Downstream Products

• 1186579-84-9 C₄₃H₅₃N₅O₁₁ 
• 1355027-79-0 tert-butyl [2-(2,2-dimethyl-4,24-dioxo-3,8,11,14,17,20-hexaoxa-5,23-diazahexacosan-26-yl)-4-{[(4-{[(2,6-dimethylphenyl)carbamoyl]amino}phenyl)acetyl]amino}phenoxy]acetate 
• 1355027-66-5 [2-(21-amino-3-oxo-7,10,13,16,19-pentaoxa-4-azahenicos-1-yl)-4-{[(4-{[(2,6-dimethylphenyl)carbamoyl]amino}phenyl)acetyl]amino}phenoxy]acetic acid trifluoroacetate 

Relevant articles and documents

COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION

The invention relates to activated Michael acceptor (AMA) compounds that can undergo conjugation with biomolecules containing Michael donor moieties, thereby providing plasma-stable antibody-drug conjugates (ADCs). Pharmaceutical compositions of the ADCs are disclosed as well. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.

EXENATIDE MODIFIER AND USE THEREOF

Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.

LDV peptidomimetics equipped with biotinylated spacer-arms: Synthesis and biological evaluation on CCRF-CEM cell line

The tripeptide Leu-Asp-Val (LDV) is known to bind α4β 1 integrin in leukemia cells. Here we have synthesized a LDV peptidomimetic equipped with a biotin-conjugated spacer-arm. Compound 9 acts as an inhibitor of the α4β1 integrin in an adhesion assay using fluorescently labeled, α4β 1 integrin-expressing leukemia CCRF-CEM cells. Furthermore, when bound to neutravidin-coated plates, compound 9 could capture CCRF-CEM cells. Such biotin-conjugated LDV peptidomimetic may thus represent a novel tool for biotechnological applications using avidin interaction for leukapheresis or leukemia cell targeting.